Companies › Passage Bio
1 active drug program in 1 registered trial: 1 Phase 1; Neurology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PBFT02 Gene therapy delivering functional GRN gene to the brain | GRN | Phase 1 | Frontotemporal Dementia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04747431 | PBFT02 | Phase 1 | Frontotemporal Dementia | Neurology | Jun 2026 |
Cash and short-term investments of $20m on 2026-09-30; operating cash outflow about $35m a year; runway about 7 months at that burn, to Apr 2027
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.